Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis
详细信息 查看全文
- 作者：Rachel Harrington ; Edward Lee ; Hongbo Yang ; Jin Wei ; Andrew Messali…
- 关键词：Cost ; effectiveness ; Invasive aspergillosis ; Infectious diseases ; Isavuconazole ; Phase III trial ; Sensitivity analyses ; Voriconazole
- 刊名：Advances in Therapy
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：34
- 期：1
- 页码：207-220
- 全文大小：590KB
- 刊物主题：Internal Medicine; Oncology; Cardiology; Rheumatology; Endocrinology; Pharmacology/Toxicology;
- 出版者：Springer Healthcare
- ISSN：1865-8652
- 卷排序：34
文摘
IntroductionInvasive aspergillosis (IA) is associated with a significant clinical and economic burden. The phase III SECURE trial demonstrated non-inferiority in clinical efficacy between isavuconazole and voriconazole. No studies have evaluated the cost-effectiveness of isavuconazole compared to voriconazole. The objective of this study was to evaluate the costs and cost-effectiveness of isavuconazole vs. voriconazole for the first-line treatment of IA from the US hospital perspective.